BRIJ Medical, Inc.

BRIJ Medical manufactures Brijjit, a biocompatible, non-invasive force-modulating tissue bridge (final skin closure device) designed to actively offload incisional tension during the final stage of surgical closure. The device is placed on the skin surface (not subcutaneously) and provides up to 100% active tension offloading into sub-cutaneous tissue, enabling healing from the inside out. Brijjit is indicated for use across plastic surgery (breast reduction, mastopexy, lipoma removal, brachioplasty, abdominoplasty), orthopedic surgery (quad tendon repair, total ankle reconstruction, knee surgery, hip surgery), and podiatric surgery (foot and ankle procedures). The company reports clinical evidence from randomized controlled trials (RCT at UT Southwestern) demonstrating 90% reduction in wound breakdown in breast surgery and 38% reduction in scar size. Additional clinical data from five trials show no reported allergic reactions; the device is hypoallergenic, waterproof, breathable, and supports wear time of 10–14+ days. Brijjit is available in two sizes. The product is adopted by major U.S. healthcare systems including Duke Health, UCSF Medical Center, Emory Healthcare, Kaiser Permanente, and Ochsner Health System. The company operates a direct-to-provider e-commerce platform and offers no-cost evaluation kits for qualifying facilities.